Half-Year 2022 Financial and Clinical Trials Update

Gantenerumab (RG1450) Fully human monoclonal antibody binding aggregated forms of AB Indication Prodromal to mild Alzheimer's disease Phase/study # of patients Phase III GRADUATE 1 N=1,016 104-week SC treatment period: ARM A: Gantenerumab Design ☐ ARM B: Placebo Phase III GRADUATE 2 N=1,016 104-week SC treatment period: ARM A: Gantenerumab ARM B: Placebo ■ Change in CDR-SOB at 27 months Primary endpoint Status CT Identifier ▪ Change in CDR-SOB at 27 months FPI Q3 2018 Phase II GRADUATION N=192 104-week SC treatment period: gantenerumab SC treatment q1w dosing regimen Change from baseline in deposited amyloid (PET centiloid levels) ▪ Recruitment completed Q3 2021 FPI Q2 2018 ☐ ■ FPI Q4 2020 Recruitment completed Q2 2020 ▪ Recruitment completed Q2 2020 BTD granted by FDA Sep 2021 NCT03443973 NCT03444870 In collaboration with MorphoSys AG AB-amyloid-beta; CDR-SOB-Clinical Dementia Rating Scale Sum of Boxes; SC-Subcutaneous; BTD=Breakthrough Therapy Designation; PET= positron emission tomography NCT04592341 Roche 144 Neuroscience

View entire presentation